Accuracy Coverage Pricing Help Centre Contact
Astrazeneca plc

Astrazeneca plc (AZN) Dividends

Dividend Summary:

The next Astrazeneca plc dividend will go ex in 9 days for 90c and will be paid in 1 month.
The previous Astrazeneca plc dividend was 190c and it went ex 5 months ago and it was paid 4 months ago.
There are typically 2 dividends per year (excluding specials), and the dividend cover is approximately 1.3.
Country:
United Kingdom
Exchange:
London Stock Exchange
Sector:
Pharmaceuticals & Biotechnology
  Previous Dividend Next Dividend
Status: Paid Declared
Type: Interim Interim
Per Share: 153.391p (190c) Sign Up Required
Ex-div Date: Thu 27 Feb 2020 Thu 13 Aug 2020
Pay Date: Mon 30 Mar 2020 Mon 14 Sep 2020
Your Holding: 100 shares 100 shares
Your Payment: £153.39 ($190.00) £68.83 ($90.00)

Dividend Payment Calculator

Enter the number of shares you hold:

shares
Calculate Payment

Free dividend email notifications

Declared and Forecast Astrazeneca plc Dividends

Ex-Div Date Pay Date Type Amount Currency Status
31 Dec 2006 31 Dec 2006 Final 89.6p GBP Paid
31 Dec 2007 31 Dec 2007 Final 93p GBP Paid
31 Dec 2008 31 Dec 2008 Final 132.6p GBP Paid
31 Dec 2009 31 Dec 2009 Final 141.4p GBP Paid
04 Aug 2010 13 Sep 2010 Interim 44.9p GBP Paid
02 Feb 2011 14 Mar 2011 Final 116.7p GBP Paid
03 Aug 2011 12 Sep 2011 Interim 51.9p GBP Paid
08 Aug 2012 10 Sep 2012 Interim 58.1p (90c) USD Paid
13 Feb 2013 18 Mar 2013 Final 120.5p (190c) USD Paid
14 Aug 2013 16 Sep 2013 Interim 59.2p (90c) USD Paid
19 Feb 2014 24 Mar 2014 Final 116.56p (190c) USD Paid
13 Aug 2014 15 Sep 2014 Interim 53.22p (90c) USD Paid
19 Feb 2015 23 Mar 2015 Final 125p (190c) USD Paid
13 Aug 2015 14 Sep 2015 Interim 57.69p (90c) USD Paid
18 Feb 2016 21 Mar 2016 Final 130.38p (190c) USD Paid
11 Aug 2016 12 Sep 2016 Interim 68.7p (90c) USD Paid
16 Feb 2017 20 Mar 2017 Final 150.2p (190c) USD Paid
10 Aug 2017 11 Sep 2017 Interim 68.9p (90c) USD Paid
15 Feb 2018 19 Mar 2018 Final 133.6p (190c) USD Paid
09 Aug 2018 10 Sep 2018 Interim 69.618p (90c) USD Paid
28 Feb 2019 27 Mar 2019 Final 143.2p (190c) USD Paid
08 Aug 2019 09 Sep 2019 Interim 72.905p (90c) USD Paid
27 Feb 2020 30 Mar 2020 Interim 153.391p (190c) USD Paid
13 Aug 2020 14 Sep 2020 Interim Sign Up Required USD Declared
11 Feb 2021 15 Mar 2021 Final Sign Up Required USD Forecast
05 Aug 2021 06 Sep 2021 Interim Sign Up Required USD Forecast
10 Feb 2022 14 Mar 2022 Final Sign Up Required USD Forecast
11 Aug 2022 12 Sep 2022 Interim Sign Up Required USD Forecast
09 Feb 2023 13 Mar 2023 Final Sign Up Required USD Forecast
10 Aug 2023 11 Sep 2023 Interim Sign Up Required USD Forecast
08 Feb 2024 11 Mar 2024 Final Sign Up Required USD Forecast
08 Aug 2024 09 Sep 2024 Interim Sign Up Required USD Forecast
06 Feb 2025 10 Mar 2025 Final Sign Up Required USD Forecast

How accurate are our Astrazeneca plc forecasts?

Prediction Date Dividend Date Forecast Amount Actual Amount Accuracy
14 Feb 2020 13 Aug 2020 90c 90c 100% 😄
25 Oct 2019 13 Aug 2020 90c 90c 100% 😄
25 Oct 2019 27 Feb 2020 190c 190c 100% 😄
07 Feb 2019 28 Feb 2019 190c 190c 100% 😄
26 Jul 2018 08 Aug 2019 90c 90c 100% 😄
19 Jul 2018 13 Aug 2020 90c 90c 100% 😄
02 Feb 2018 09 Aug 2018 90c 90c 100% 😄
02 Feb 2018 28 Feb 2019 190c 190c 100% 😄
02 Feb 2018 27 Feb 2020 190c 190c 100% 😄
07 Nov 2017 15 Feb 2018 190c 133.6p 100% 😄
16 Feb 2017 15 Feb 2018 150p 133.6p 88% 😏
02 Feb 2017 28 Feb 2019 150p 190c 88% 😏
02 Feb 2017 10 Aug 2017 68.7p 68.9p 86% 😏
28 Jul 2016 09 Aug 2018 68.7p 90c 86% 😏
28 Jul 2016 15 Feb 2018 144p 133.6p 86% 😏
28 Jul 2016 16 Feb 2017 144p 150.2p 86% 😏
28 Jul 2016 10 Aug 2017 68.7p 68.9p 86% 😏
04 Feb 2016 15 Feb 2018 130p 133.6p 81% 😌
04 Feb 2016 16 Feb 2017 130p 150.2p 81% 😌
30 Jul 2015 10 Aug 2017 60p 68.9p 80% 😌
05 Feb 2015 11 Aug 2016 60p 68.7p 80% 😌
Average Astrazeneca plc Forecast Accuracy 92% 😊

Access our Astrazeneca plc dividend forecasts and the suite of investor tools free for 30 days.

Try DividendMax free for 30 days

About Astrazeneca plc

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium. Revenues over the next couple of years are forecast to fall. The dividend track record is excellent and an increased payout is forecast in spite of the falling revenues.

AstraZeneca dividends

AstraZeneca has a progressive dividend policy, intending to maintain or grow the dividend each year.

Payment of dividends

  1. First interim: announced end of July and paid in September
  2. Second interim: announced end of of January/beginning of February and paid in March

Fundamentals

Optimized Dividends

Annual Dividends

Year Amount Change
2006 89.6p
2007 93.0p 3.8%
2008 132.6p 42.6%
2009 141.4p 6.6%
2010 161.6p 14.3%
2011 51.9p (67.9%)
2012 178.6p 244.1%
2013 175.76p (1.6%)
2014 178.22p 1.4%
2015 188.07p 5.5%
2016 218.9p 16.4%
2017 202.5p (7.5%)
2018 212.8184p 5.1%
2019 226.2953p 6.3%
2020 Login required
2021 Login required
2022 Login required
2023 Login required
2024 Login required

Dividends

Ex-Div Date Pay Date Year Type Frequency Status Amount
04 Aug 2010 13 Sep 2010 2010 Interim Semiannually Paid 44.9p
02 Feb 2011 14 Mar 2011 2010 Final Semiannually Paid 116.7p
03 Aug 2011 12 Sep 2011 2011 Interim Semiannually Paid 51.9p
08 Aug 2012 10 Sep 2012 2012 Interim Semiannually Paid 58.1p (90c)
13 Feb 2013 18 Mar 2013 2012 Final Semiannually Paid 120.5p (190c)
14 Aug 2013 16 Sep 2013 2013 Interim Semiannually Paid 59.2p (90c)
19 Feb 2014 24 Mar 2014 2013 Final Semiannually Paid 116.56p (190c)
13 Aug 2014 15 Sep 2014 2014 Interim Semiannually Paid 53.22p (90c)
19 Feb 2015 23 Mar 2015 2014 Final Semiannually Paid 125p (190c)
13 Aug 2015 14 Sep 2015 2015 Interim Semiannually Paid 57.69p (90c)
18 Feb 2016 21 Mar 2016 2015 Final Semiannually Paid 130.38p (190c)
11 Aug 2016 12 Sep 2016 2016 Interim Semiannually Paid 68.7p (90c)
16 Feb 2017 20 Mar 2017 2016 Final Semiannually Paid 150.2p (190c)
10 Aug 2017 11 Sep 2017 2017 Interim Semiannually Paid 68.9p (90c)
15 Feb 2018 19 Mar 2018 2017 Final Semiannually Paid 133.6p (190c)
09 Aug 2018 10 Sep 2018 2018 Interim Semiannually Paid 69.618p (90c)
28 Feb 2019 27 Mar 2019 2018 Final Semiannually Paid 143.2p (190c)
08 Aug 2019 09 Sep 2019 2019 Interim Semiannually Paid 72.905p (90c)
27 Feb 2020 30 Mar 2020 2019 Interim Semiannually Paid 153.391p (190c)
Sign Up Required Sign Up Required 2020 Interim Semiannually Declared Sign Up Required
Sign Up Required Sign Up Required 2020 Final Semiannually Forecast Sign Up Required
Sign Up Required Sign Up Required 2021 Interim Semiannually Forecast Sign Up Required
Sign Up Required Sign Up Required 2021 Final Semiannually Forecast Sign Up Required
Sign Up Required Sign Up Required 2022 Interim Semiannually Forecast Sign Up Required
Sign Up Required Sign Up Required 2022 Final Semiannually Forecast Sign Up Required
Sign Up Required Sign Up Required 2023 Interim Semiannually Forecast Sign Up Required
Sign Up Required Sign Up Required 2023 Final Semiannually Forecast Sign Up Required
Sign Up Required Sign Up Required 2024 Interim Semiannually Forecast Sign Up Required
Sign Up Required Sign Up Required 2024 Final Semiannually Forecast Sign Up Required

Recent news articles

Investment Tools Limited

The AstraZeneca Board has recommended an unchanged first interim dividend of $0.90 (69.6 pence, 7.87 SEK) per Ordinary Share.

Read more
Investment Tools Limited

Following recommendation from the board, AstraZeneca have maintained their dividend at $0.90.

Read more
Investment Tools Limited

Financial Highlights

Read more
Investment Tools Limited

Core EPS in the year up by 7% and by 22% in Q4 2015

Read more
Investment Tools Limited

Total H1 Revenue up 1%; Core Gross margin over 83%, up 1% point

Read more
Investment Tools Limited

Financial results for 2014 in line with upgraded Company guidance given with third quarter 2014 results.

Read more
Investment Tools Limited

Revenue in the second quarter was $6,454 million, up 4%* - second consecutive quarter of revenue growth. Half year revenue up 3%, driven by the five growth platforms.

Read more
Investment Tools Limited

As expected, third quarter revenue declined due to the ongoing impact from products with recent losses of exclusivity.  The 4 percent decline in revenue on a constant currency basis, combined with continued investment in our growth platforms and scientific leadership resulted in a greater decline in Core earnings per share.  The late-stage pipeline continued to grow; since the half year update there have been three new Phase III programme starts and three regulatory filings were accepted for review.

Read more
Investment Tools Limited

Investors Chronicle – Dividend of the week – Number fifteen

Read more
Investment Tools Limited

Revenue in the second quarter declined by 4 percent at constant exchange rates (CER), as the impact from products with recent loss of exclusivity has moderated from the levels experienced in recent quarters. Revenue for the rest of the portfolio was up 4 percent, fuelled by a double-digit increase from the five growth platforms. The pipeline was further strengthened by the addition of three promising late-stage assets in core therapeutic areas of cardiovascular/metabolism and respiratory diseases. 

Read more

Astrazeneca plc optimized dividend - 12 month history